Last edition
News about
YolTech and KACTUS to Accelerate DNA Editing System in Greater China
YolTech has teamed up with KACTUS to advance the commercialization of YolTech's proprietary DNA editor, YolCas12, in Greater China.
Haemonetics Releases Limited Market Release for New VASCADE MVP XL Vascular Closure Device
Haemonetics Corp. has rolled out a limited market release of its new VASCADE MVP XL mid-bore venous closure device.
Ascidian Partners with Roche for Development of RNA Exon Editing Therapeutics
Ascidian Therapeutics has signed a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Wisconsin
Thermo Fisher Scientific’s PPD clinical research business has launched a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin.
Spyre Announces First Participants Dosed in Phase 1 Trial of SPY001
Spyre Therapeutics, Inc. announced that it has initiated dosing of healthy volunteers in its first clinical trial of SPY001, an investigational novel half-life extended anti-α4β7 monoclonal antibody.
Ethypharm Signs Deal with MTPC to Acquire Argatroban Monohydrate
Ethypharm has signed an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra, Arganova, Novastan, Exembol), in Europe.
Alembic Pharmaceuticals Gets Approval from USFDA for its Injection to Treat Rare Genetic Condition
The US Food & Drug Administration (USFDA) has granted Alembic Pharmaceuticals Limited final clearance for its Abbreviated New Drug Application (ANDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.
Lupin Names Abdelaziz Toumi as CEO of its Subsidiary
Lupin has appointed Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS).
Labcorp Rolls Out Global Trial Connect to Accelerate Clinical Trials
Labcorp has launched Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.
Northwest Biotherapeutics Bags Exclusive In-License of Dendritic Cell Technology
Northwest Biotherapeutics has announced an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy